Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
Objectives:

* To determine the maximum tolerated dose of oral topotecan when administered with Temodar to patients with malignant glioma
* To characterize any toxicity associated with the combination oral topotecan and Temodar.
* To observe patients for clinical antitumor response when treated with oral topotecan and Temodar.
Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma
DRUG: Oral Topotecan and Temodar
maximum tolerated dose, 6 months
Safety & efficacy, 6 months
Subjects are patients with glioblastoma (GBM), anaplastic astrocytoma (AA) or grade 3 or greater WHO astrocytic, oligodendroglial or mixed glial tumors, which were initially diagnosed by histologic examination of biopsy/resection. Modified classical "3+3" phase I design used to determine maximum tolerated dose of topotecan in combination with Temodar.